Skip To The Main Content
PDA News


New Year, New Name, New Activities for BioAB

Mar 06, 2017

PDA’s Biotechnology Advisory Board is now officially the Biopharmaceutical Advisory Board (BioAB). This new name better represents the scientific and technical information this advisory board provides to PDA’s board of directors and its membership regarding biopharmaceutical manufacturing, quality and regulations.

But BioAB is more than an advising group. Its members actively participate and take leadership roles in numerous PDA events. And 2017 is proving to be an active year with BioAB members involved in three major upcoming events:

2017 PDA Annual Meeting

Michael De Felippis, PhD, Senior Research Fellow, Bioproduct R&D, Eli Lilly & Company and Vice-Chair of BioAB, and Morten Munk, Senior Technology Partner, Global Business Development, NNE Pharmaplan, are co-chairing this signature PDA event in April, assisted by Laurie Graham, Acting Director, OPQ, US FDA, and a number of other PDA volunteer members from across the bio/pharmaceutical industry on the conference planning committee.

2017 PDA Cell and Gene Therapy Workshop

Due to the increasing importance of cell and gene therapy products, BioAB has designated this area of biopharma as a major initiative for the advisory board, led by volunteers Vijay Chiruvolu, PhD, Senior Director, Product Sciences, Kite Pharma, Michael Blackton, Vice President, QA CMC, Adaptimmune, and Karen Walker, Global Head, Quality, Cell and Gene Therapy Units, Novartis. All three have been heavily involved in developing this workshop on these “next wave” biopharmaceutical products. It is scheduled to follow the Annual Meeting in April.

2017 PDA Biosimilars Conference

Vince Anicetti, Executive Director, Quality, Coherus Bioscience, and Stephan Krause, PhD, Director, QA Technology, AstraZeneca Biologics, are co-chairing this year’s biosimilars conference in June, assisted by Michael VanDerWerf, Director, Regulatory Affairs, Teva, Laurie Graham, and Jens Schletter, PhD, Head, Regulatory CMC Group Biopharmaceuticals, Sandoz. BioAB has been heavily involved in this area as biosimilars are already market-approved in both Europe and the United States, with many more in various stages of clinical development or under active regulatory authority market approval review.

PDA’s BioAB members continue to work hard to cover emerging developments and technology in biopharma. The advisory board hopes these three PDA events offer members a chance to learn more about the latest biopharmaceutical trends and challenges as well as debate these topics with other members.


comments powered by Disqus